22 completed, 3 terminated, 3 withdrawn, 1 active not recruiting. 21 Phase 2, 10 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 15, Terminated 2, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 1 | 10 | Completed 8, Active not recruiting 1, Terminated 1 |
| Not applicable | 1 | Withdrawn 1 |
Follow ZIV-Aflibercept: new trials by email Literature Review of ZIV-Aflibercept trials Research Report on ZIV-Aflibercept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma ZIV-Aflibercept, Cemiplimab - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2024-11-04 | 2025-12-04 |
| Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma Stereotactic Body Radiation Therapy, Ziv-Aflibercept - Uveal Melanoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 3 | 2019-08-09 | 2025-09-24 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 59 | 2015-04-08 | 2026-10-07 |
| Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer ziv-aflibercept, leucovorin calcium, fluorouracil - Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum | Phase 2 | Withdrawn | University of Southern California | 2015-03-01 | 2015-05-06 | |
| Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection ziv-aflibercept - Neovascularization, Macular Degeneration | Phase 2 | Unknown | Rafic Hariri University Hospital | 100 | 2015-03-01 | 2018-08-29 |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas Ziv-Aflibercept, Ganetespib - Neoplasms | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2014-12-02 | 2018-03-29 |
| Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer 5-FU, LV, ziv-aflibercept - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Withdrawn | NSABP Foundation Inc | 2014-11-01 | 2014-12-02 | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Sapanisertib, Ziv-Aflibercept - Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 83 | 2014-06-18 | 2025-10-20 |
| Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept - Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2014-06-18 | 2020-03-23 |
| Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy ziv-aflibercept, leucovorin calcium, irinotecan hydrochloride - Recurrent Colon Cancer, Recurrent Rectal Cancer | Not applicable | Withdrawn | City of Hope Medical Center | 2014-01-01 | 2014-07-21 | |
| Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors Ziv-aflibercept - Carcinoid Tumor | Phase 2 | Completed | Dana-Farber Cancer Institute | 19 | 2013-02-13 | 2023-08-14 |
| FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer Oxaliplatin, Leucovorin, Fluorouracil - Esophageal Cancer, Gastric Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 64 | 2013-01-01 | 2020-02-10 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept - Metastatic Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 84 | 2011-01-18 | 2019-05-10 |
| S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer ziv-aflibercept, topotecan hydrochloride - Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 189 | 2009-05-01 | 2017-08-21 |
| Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2008-08-01 | 2017-03-15 |
| Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma ziv-aflibercept, radiation therapy, temozolomide - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Completed | National Cancer Institute (NCI) | 61 | 2008-07-01 | 2014-05-30 |
| Aflibercept in Treating Young Patients With Relapsed or Refractory Solid Tumors ziv-aflibercept - Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2008-04-01 | 2014-02-24 |
| Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer VEGF Trap - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 94 | 2007-12-01 | 2017-06-23 |
| VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer ziv-aflibercept - Recurrent Endometrial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 49 | 2007-11-01 | 2019-07-23 |
| Aflibercept in Treating Patients With Myelodysplastic Syndromes ziv-aflibercept, laboratory biomarker analysis, pharmacological study - Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2007-09-01 | 2015-01-08 |
Showing 20 of 31. Sign in to see all of them.
Burkitt Lymphoma (4) · Carcinoma, Ovarian Epithelial (4) · Fallopian Tube Neoplasms (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Follicular (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, Non-Hodgkin (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Sarcoma (4) · Colonic Neoplasms (3) · Endometrial Neoplasms (3) · Melanoma (3)
National Cancer Institute (NCI) (19) · Regeneron Pharmaceuticals (4) · Dana-Farber Cancer Institute (2) · City of Hope Medical Center (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · NSABP Foundation Inc (1) · Rafic Hariri University Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Southern California (1)
United States (28) · Canada (3) · Lebanon (1) · Peru (1)
Ahmad Tarhini (2) · Jakob Dupont, MD (2) · Robert Coleman (2) · William P. Tew, MD (2) · Afsaneh Barzi (1) · Ahmad M Mansour, MD (1) · Ahmad Tarhini, MD, PHD (1) · Alice P Chen, M.D. (1) · Amit Oza (1) · Aung Naing (1) · Daniel Halperin (1) · David Pfister (1) · Edith Perez (1) · Frank S Hodi (1) · Jeffrey Allen (1)
PMID 19949018, PMID 20028764, PMID 22002018, PMID 21632852, PMID 21992853, PMID 22922531, PMID 25002722, PMID 25490004, PMID 25677668, PMID 27030277, PMID 28614154, PMID 29853657, PMID 31956432, PMID 35264434, PMID 36395401, PMID 38236249, PMID 39207600
N01CM62209 (5), N01CM62201 (2), N01CM62203 (2), P30CA016672 (2), P30CA033572 (2), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM62206 (1), P30CA008748 (1), P30CA014089 (1), P50CA083639 (1), U01CA062399 (1), U01CA062461 (1)